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Metformin Use and Severe Dengue 
in Diabetic Adults
Htet Lin Htun  1, Tsin Wen Yeo1,2, Clarence C. Tam3,4, Junxiong Pang3, Yee Sin Leo1,2,3,5 & 
David C. Lye1,2,5
Diabetes mellitus is a risk factor for severe dengue in adults, but few studies have examined the 
association between metformin use and disease severity in dengue. In addition to its effect on glucose 
control, metformin has been associated with pleiotropic properties in preclinical studies. Using a cohort 
of laboratory-confirmed adult (≥21 years) dengue patients with diabetes mellitus admitted to Tan 
Tock Seng Hospital, we conducted a retrospective cohort study involving 131 (58.7%) metformin users 
and 92 (41.3%) non-users. Dengue severity was categorized as dengue hemorrhagic fever (DHF) or 
dengue shock syndrome (DSS) in World Health Organization (WHO) 1997 criteria and severe dengue 
(SD) in WHO 2009 criteria. Multivariable Poisson regression with robust error variance was used to 
estimate risk ratio (RR). Compared with non-use, metformin use was associated with a decreased risk 
of developing severe dengue (adjusted risk ratio [aRR] = 0.60, 95% confidence interval [CI]: 0.37–0.98, 
P = 0.04). Additionally, there was an inverse dose-response relationship (aRR = 0.69, 95% CI: 0.49–0.98, 
P = 0.04) with dengue severity as classified by WHO 2009 criteria. Use of metformin, however, was not 
associated with dengue severity based on WHO 1997 criteria; and no dose-response relationship was 
noted. Our results suggest metformin use could attenuate disease severity in dengue-infected diabetes 
mellitus individuals.
Dengue is the most common arthropod-borne viral infection, and the number of reported cases are increasing 
in the Western Pacific, the Americas and even Europe1. It is caused by four antigenically distinct serotypes of 
dengue viruses (DENV-1, DENV-2, DENV-3 and DENV-4) belonging to the Flavivirus family, all of which are 
transmitted by the Aedes aegypti and Aedes albopictus mosquitoes2. An estimated 390 million dengue infections 
occur worldwide each year, including 96 million with clinical symptoms. Asia is projected to have the highest 
burden, with 273 million infections annually3. Dengue infection manifests from asymptomatic infection to mild 
undifferentiated fever to a severe life-threatening condition. The World Health Organization (WHO) 1997 and 
the more recent WHO 2009 dengue classification criteria are the two most common classification criteria used 
to define dengue severity.
Against this background of increasing dengue incidence worldwide, the non-communicable disease burden is 
also growing. Among this group, diabetes mellitus (DM) is one of the most important and prevalent. According 
to the WHO, DM currently affects 347 million individuals worldwide, and it is predicted to be the seventh lead-
ing cause of death by 20304. Of all the oral hypoglycemic agents (OHAs) to treat DM, metformin which belongs 
to the biguanide family is the most commonly prescribed and widely used agent. The blood glucose lowering 
action of metformin is achieved by suppressing gluconeogenesis5 and increasing peripheral tissue sensitivity to 
insulin6,7. In addition, metformin has also been demonstrated to have multiple pleiotropic actions including 
anti-inflammatory8, immunomodulatory9, anti-cancerous10, cardio-protective and vasculo-protective actions11 
and limits the growth of micro-organisms12–14. Given dengue pathogenesis is a complex intertwined process 
involving the humoral and cellular immune systems, inflammatory cytokines and chemical mediators15, there 
may be a potential reduction in the risk of severe dengue manifestations among diabetic patients on metformin 
treatment because of immunomodulatory and anti-inflammatory properties.
Many observational studies have identified DM as an independent risk factor for severe dengue16–19. On the 
other hand, several observational studies in Asia and Europe have suggested a reduced risk of viral or bacterial 
1Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. 2Lee Kong Chian 
School of Medicine, Nanyang Technological University, Singapore, Singapore. 3Saw Swee Hock School of Public 
Health, National University of Singapore, Singapore, Singapore. 4Department of Infectious Diseases Epidemiology, 
London School of Hygiene and Tropical Medicine, London, United Kingdom. 5Yong Loo Lin School of Medicine, 
National University of Singapore, Singapore, Singapore. Correspondence and requests for materials should be 
addressed to T.W.Y. (email: tsin_wen_yeo@ttsh.com.sg)
Received: 31 August 2017
Accepted: 2 February 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIfIC RePoRTS |  (2018) 8:3344  | DOI:10.1038/s41598-018-21612-6
infections and infection-related complications in metformin users12,20,21. To our knowledge, no studies have 
examined the role of metformin on dengue disease severity among diabetic patients independent of its effect on 
blood glucose.
We performed a retrospective cohort study among adult DM patients with acute dengue infection to evaluate 
the association between metformin use and risk of severe dengue, using both WHO 1997 and WHO 2009 dengue 
classification criteria.
Methods
Setting and data source. The study included patients admitted to the Department of Infectious Diseases, 
Tan Tock Seng Hospital (TTSH), the largest university teaching hospital in Singapore in dengue treatment. The 
source population was identified from three previous hospital-based dengue studies conducted in TTSH in 
200422, 2005–200823 and 2012–2013. All of these studies included adult laboratory-confirmed dengue patients i.e., 
either positive dengue polymerase chain reaction (PCR)24 or non-structural protein 1 (NS1) antigen tests based 
on a single acute sample25,26. The databases of the three studies provided information on demographics, dengue 
laboratory test results, comorbidities and detailed clinical data for the present study.
Study design and population. We conducted a hospital-based retrospective cohort study among adult 
(≥21 years) diabetic patients presenting with dengue. From the described source population, the study popula-
tion was selected with the following eligibility criteria:
 a. Clinical manifestations of acute dengue infection according to WHO 1997 or 2009 guidelines with labora-
tory confirmation by either positive dengue PCR24 or NS1 antigen25,26 and
 b. Documented history of DM in hospital electronic medical records. Gestational diabetes without progres-
sion to DM was excluded.
Exposure data. Participants were followed up from the date of presentation with dengue. The exposure of 
interest was current treatment with metformin assessed by tracking the most recent prescription from hospital 
medication prescription database records in 180 days prior to hospital presentation. Metformin usage was con-
firmed with medication reconciliation records performed by hospital pharmacists which listed all the medications 
patients were taking before hospitalization. Patients were classified as metformin users if they were on metformin 
treatment at the time of presentation and non-users otherwise. Metformin exposure was categorized as follows:
•	 Users: When there was a record for metformin use in the 180 days prior to hospital presentation, the prescrip-
tion start date and duration of drug supply were collected to calculate the prescription end date. Patients were 
categorized as metformin users if the prescription end date was on or after the hospitalization date for dengue.
•	 Non-users: Patients with a metformin prescription ending before the hospital presentation date, or without 
any record of metformin use, were categorized as non-users.
•	 Prescribed metformin doses: Data on metformin dose was extracted for each user and was computed by mul-
tiplying the prescribed dose by daily prescription frequency.
Outcome data. The study outcome, dengue severity was categorized as dengue hemorrhagic fever (DHF) 
and dengue shock syndrome (DSS) based on WHO 1997 criteria and severe dengue (SD) according to WHO 
2009 criteria. Patients were retrospectively classified into the two WHO dengue criteria with available clinical, 
laboratory and radiological data in each study using the same criteria across all previous studies. Clinical variables 
during hospital stay were documented using a standardized dengue care path for all dengue patients and the data 
were extracted by medically trained research assistants from the first day of hospital presentation until discharge 
date for inpatients, and to the end of acute follow-up for outpatients.
WHO 1997 classification. Dengue fever (DF) was diagnosed when there was fever and two or more of: headache, 
eye pain, myalgia, arthralgia, rash, hemorrhagic manifestations or leucopenia. DHF was diagnosed when there 
was fever and all three of: hemorrhagic manifestations; thrombocytopenia <100 × 109/L; and plasma leakage 
evidenced by pleural effusion or ascites or change in haematocrit ≥20% or hypoproteinaemia. To classify as DSS, 
there must be DHF as well as additional criteria including tachycardia with narrow pulse pressure lower than 
20 mmHg or hypotension for age (systolic blood pressure <90 mmHg)27.
WHO 2009 classification. Probable dengue was diagnosed when there was fever and two or more of: nausea, 
vomiting, rash, aches and pains, leukopenia and presence of any warning signs which include abdominal pain 
or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy or restlessness, liver 
enlargement >2 cm and increase in hematocrit concurrent with rapid decrease in platelet count. Severe dengue 
was defined as: (i) severe plasma leakage with respiratory distress or shock; (ii) severe bleeding defined as a min-
imum of WHO grade 2 bleeding scale including hematemesis, melena, hematochezia, hematuria, menorrhagia, 
hemoptysis or any other bleeding that required whole blood or packed red cell transfusion; (iii) severe organ 
involvement defined by either acute liver injury – aspartate transaminase (AST) and alanine transaminase (ALT) 
≥1000 unit/L or acute kidney injury or encephalopathy or myocarditis28.
Potential confounders. Covariates likely to be associated with dengue severity and likelihood of 
receiving metformin treatment were identified. These covariates were measured at the same time period as 
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metformin exposure. Potential confounders included age29, gender30, ethnicity31, obesity32,33 as defined by 
body mass index (BMI) ≥30 kg/m2, smoking, and concurrent medications including other OHAs, statins, 
angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB)34. Dengue serotype 
is known to influence disease severity in Singapore35. However, patient-specific dengue serotype data for each 
subject was unavailable; thus the year of presentation was used as a surrogate index to estimate dominant circu-
lating serotype in each epidemic year. Based on the Singapore communicable diseases surveillance data published 
by Ministry of Health Singapore, during the year of 2004 to 2006 and 2013, DENV-1 serotype predominated 
(61–82% of all circulating serotypes), and DENV-2 was the predominant serotype during 2007–2008 and 2012 
(66–87%)36.
Comorbidities were measured by Charlson’s comorbidity index (CCI)37, and other comorbidities included 
hypertension, hyperlipidemia, allergy and past dengue38. Diabetes control was determined using glycated hemo-
globin (HbA1c)39 measured in the 3 months prior to the dengue presentation date and categorized into ≤7.0% 
(optimal), 7.1–8.0% (suboptimal) and >8.0% (unacceptable). The diabetes complications severity index (DCSI)40, 
a validated 13-point clinical tool from seven categories of diabetes-related complications, was also included as a 
potential confounder. The decision to prescribe metformin depends on the renal function of patients. Therefore, 
serum creatinine >2.0 mg/dL and nephropathy on admission described in previous study40 were included. The 
diagnostic data to compute CCI and DCSI were drawn from the TTSH healthcare intelligence (TTSH-HI) system 
using the validated International Classification of Diseases Ninth Revision, Clinical Modification (ICD-9-CM) 
coding algorithms based on inpatient and outpatient encounters registered in TTSH-HI before the admission 
date. TTSH-HI is an integrated system with consolidated information from different sources to allow retrieval of 
structured variables such as demographic, clinical, laboratory and medication prescription data of each subject.
Data collection. Microsoft Access database 2013 was used to collect, manage and collate the data. Data 
extraction was performed by two trained research assistants independently following standardized data collection 
procedures. Rule-based data validation was performed through the entire dataset to ensure data integrity and 
internal consistency. Additionally, 20% of the subjects were randomly selected for repeat data entry by another 
research assistant, and data discrepancies were resolved by independent source document verification by a senior 
medically-trained study team member. All subject identifiers were anonymized for analysis.
Statistical methods. Characteristics of metformin users and non-users were described with frequencies 
and percentages, and median and interquartile range (IQR) for categorical and continuous variables respectively. 
Pearson’s chi-square test or Fisher’s exact test for categorical variables and Mann-Whitney U test for continuous 
variables were used for bivariate inference methods. We used Poisson regression with robust error variance41 to 
assess the association between metformin use and severe dengue manifestations, adjusting for potential con-
founding variables. In order to build the model, a forward stepwise variable selection approach was used to 
add the a priori defined clinically important variables including age, gender, ethnicity, CCI, DCSI, nephropathy, 
serum creatinine >2.0 mg/dL, HbA1c, year of presentation and variables with P < 0.20 between the metformin 
non-users and users. The best fit model, eventually, was compared against nested models evaluating with Akaike 
information criterion (AIC). Univariable and multivariable Poisson regression with robust error variance analyses 
provided crude and adjusted risk ratio (cRR and aRR) respectively with 95% confidence interval (CI). As a sec-
ondary analysis, the linear trend of dose-response relationship was studied and prescribed metformin doses were 
also categorized into no use, ≤1500 mg and >1500 mg based on the median prescribed dose.
All statistical analyses were conducted with Stata/SE14.0 (College Station, TX: StataCorp LP). Statistical sig-
nificance was set at P < 0.05 and all reported P values were two-tailed.
Ethics consideration and STROBE statement. This study was approved by Domain Specific Review 
Board of National Healthcare Group, Singapore (DSRB – 2015/01053) with waiver of informed consent from 
subjects. This study is reported in accordance with STROBE guidelines for cohort studies (see Supplementary 
Table S1).
Data availability. All data supporting the findings of this study are available within the article and its 
Supplementary Information files, or are available from the corresponding author upon reasonable request.
Results
From 2004 to 2008 and 2012–2013, we screened 13,975 potential subjects from the three past studies and iden-
tified 230 diabetic subjects with laboratory-confirmed acute dengue. Of these, 223 subjects met the eligibility 
criteria. Among eligible patients, 131 received metformin treatment (Fig. 1).
The median age was 58 (IQR: 49–69.5) and 59 (IQR: 50–69) years for metformin non-users and users 
respectively. There were no significant differences between metformin users and non-users in terms of gender 
(P = 0.88), ethnicity (P = 0.09), proportion of overweight and obese patients (BMI ≥25–29.99 and ≥30 respec-
tively, P = 0.57), proportion of current smokers (P = 0.48), median CCI (P = 0.47), median DCSI (P = 0.60), 
nephropathy (P = 0.39), HbA1c category (P = 0.27), serum creatinine >2.0 mg/dL (P = 0.20) or predominant 
circulating serotype (P = 0.07) (Table 1). There was a statistically significant difference in the proportion of hyper-
lipidemia (P = 0.01) whereas no difference was observed for other comorbidities.
Metformin users were observed to have a lower proportion of severe dengue (42.4% in non-users v. 28.2% in 
users, P = 0.03). Amongst the three criteria of severe dengue in WHO 2009 classification, a significantly lower 
proportion of metformin users experienced severe bleeding compared with non-users (20.7% v. 9.2%, P = 0.02). 
Table 1 displayed the difference between non-users and metformin users with standard dose (≤1500 mg) and 
high dose (>1500 mg). There was a higher proportion of HbA1c >8.0% in high dose users and the difference was 
statistically significant (P = 0.03).
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Multivariable analysis based on WHO 2009 dengue classification. There were 37 (28.2%) severe 
dengue patients among metformin users and a significant inverse association was observed with metformin use 
and severe dengue on WHO 2009 classification. Compared with non-users, metformin users had a 33% reduc-
tion in a risk of severe dengue (cRR = 0.67, 95% CI: 0.46–0.96, P = 0.03) on univariable analysis. The risk reduc-
tion was 40% (aRR = 0.60, 95% CI: 0.37–0.98, P = 0.04) after controlling for age, gender, ethnicity, CCI, DCSI, 
nephropathy, hyperlipidemia, serum creatinine >2.0 mg/dL, HbA1c and concurrent medications including stat-
ins, ACEI, sulfonylurea and insulin, and year of presentation (Table 2).
On secondary analysis, there was an inverse dose-response relationship between metformin doses and severe 
dengue manifestations. Compared with non-users, the risk of severe dengue was 36% lower for patients taking 
≤1500 mg (aRR = 0.64, 95% CI: 0.39–1.04, P = 0.07) and 50% lower for those taking >1500 mg (aRR = 0.50, 95% 
CI: 0.25–0.99, P = 0.05). In addition, there was evidence supporting an inverse linear trend in this association 
(aRR = 0.69, 95% CI: 0.49–0.98, P = 0.04) (Table 2).
Multivariable analysis based on WHO 1997 dengue classification. There were 39 (29.8%) of DHF/
DSS patients among metformin users and use of metformin had no statistically significant association with den-
gue severity based on WHO 1997 classification even after adjustment of potential confounders (aRR = 0.91, 95% 
CI: 0.55–1.52, P = 0.73). Likewise, no significant dose-response relationship was observed (aRR = 1.12, 95% CI: 
0.79–1.57, P = 0.53) (Table 3).
Discussion
This retrospective cohort study of adult diabetic patients with acute dengue infection indicated that patients on 
metformin treatment had a 33–40% lower risk of developing severe dengue based on WHO 2009 dengue criteria. 
Risk of severe dengue was also significantly reduced with increasing metformin dose intensity. Based on WHO 
1997 dengue severity criteria, the association was not evident and neither was the dose-response relationship.
As the study suggested significant inverse association only for the analysis based on WHO 2009 classification, 
the relationship between metformin and severe dengue may be specific only to pathophysiology documented in 
the WHO 2009 dengue criteria. There are three severity markers in WHO 2009 dengue criteria – severe plasma 
leakage, severe bleeding and severe organ involvement. The pathogenesis of dengue virus infection leading to 
severe bleeding is complex but the major mechanisms involved can be summarized as platelet consumption, 
endothelial cell damage, imbalance profile of cytokines and chemical mediators, and suppression of hematopoie-
sis15. Investigations from in-vitro studies have found that metformin had direct vascular anti-inflammatory effect 
by attenuation of the inflammatory cytokine response8 while in-vivo studies have shown an effect of metformin 
on increasing the size of hematopoietic stem cell compartment and enhancing the quiescent state in hematopoi-
etic stem cells and progenitor cells42. The effect of metformin on endothelial cell function has been well-studied 
and many clinical and pre-clinical studies suggest that metformin improves endothelial cell function in animal 
models43,44, and also among chronic diabetic subjects45,46. Furthermore, metformin exerts antioxidant effects on 
platelets47, strengthening and stabilizing the thrombocyte colonies48. Therefore, under a causal assumption, the 
Figure 1. Flow diagram for selection of subjects.
www.nature.com/scientificreports/
5SCIENTIfIC RePoRTS |  (2018) 8:3344  | DOI:10.1038/s41598-018-21612-6
Variables
Non-users Users Users (n = 131)
P1 P2(n = 92) (n = 131)
≤1500 mg 
(n = 82)
>1500 mg 
(n = 49)
Demographic
Age - years
0.84† 0.70‡  Median (IQR) 58 (49–69.5) 59 (50–69) 60 (50–70) 58 (50–66)
  Range 25–93 29–85 35–85 29–85
Gender, n (%)
0.88 0.99  Male 44 (47.8) 64 (48.9) 40 (48.8) 24 (49.0)
  Female 48 (52.2) 67 (51.1) 42 (51.2) 25 (51.0)
Ethnicity, n (%)
0.09 0.12∫
  Chinese 62 (67.4) 92 (70.2) 62 (75.6) 30 (61.2)
  Malay 13 (14.1) 7 (5.3) 3 (3.7) 4 (8.2)
  Indian 14 (15.2) 22 (16.8) 11 (13.4) 11 (22.4)
  Others 3 (3.3) 10 (7.6) 6 (7.3) 4 (8.2)
Health Risk Factor
Body mass index (BMI), n (%)
0.57 0.25
  ≤24.99 49 (53.3) 66 (50.4) 47 (57.3) 19 (38.8)
  ≥25–29.99 28 (30.4) 48 (36.6) 26 (31.7) 22 (44.9)
  ≥30 15 (16.3) 17 (13.0) 9 (11.0) 8 (16.3)
  Current smoker, n (%) 6 (6.5) 12 (9.2) 7 (8.5) 5 (10.2) 0.48 0.70∫
Comorbidity
  Charlson’s comorbidity index (CCI) [linear] Median (IQR) 1 (1–3) 1 (1–4) 1 (1–4) 1 (1–4) 0.47† 0.55‡
Charlson’s comorbidity index (CCI) [categorical], n (%)
0.26 0.46∫
  1 52 (56.5) 71 (54.2) 42 (51.2) 29 (59.2)
  2 15 (16.3) 15 (11.4) 11 (13.4) 4 (8.2)
  3 7 (7.6) 6 (4.6) 3 (3.7) 3 (6.1)
  ≥4 18 (19.6) 39 (29.8) 26 (31.7) 13 (26.5)
Other comorbidities, n (%)
  Hypertension 61 (66.3) 99 (75.6) 59 (72.0) 40 (82.0) 0.13 0.16
  Hyperlipidemia 62 (67.4) 107 (81.7) 62 (75.6) 45 (92.0) 0.01 <0.01
  Allergy 17 (18.5) 35 (26.7) 23 (28.1) 12 (24.5) 0.15 0.32
  Past dengue 2 (2.2) 7 (5.3) 5 (6.1) 2 (4.1) 0.31∫ 0.41∫
Complications
Diabetes complications severity index (DCSI) [linear] 
Median (IQR) 0 (0–2) 0 (0–2) 0 (0–2) 0 (0–2) 0.60
† 0.86‡
Diabetes complications severity index (DCSI) [categorical], n (%)
0.95∫ 0.92∫
  0 56 (60.9) 73 (55.7) 44 (53.7) 29 (59.2)
  1 10 (10.9) 18 (13.8) 13 (15.9) 5 (10.2)
  2 9 (9.8) 16 (12.2) 12 (14.6) 4 (8.2)
  3 7 (7.6) 12 (9.2) 7 (8.5) 5 (10.2)
  4 4 (4.3) 5 (3.8) 3 (3.7) 2 (4.1)
  ≥5 6 (6.5) 7 (5.3) 3 (3.7) 4 (8.2)
  Nephropathy, n (%) 18 (19.6) 32 (24.4) 21 (25.6) 11 (22.5) 0.39 0.63
Laboratory values
Glycated hemoglobin (HbA1c), n (%)
0.27∫ 0.03∫
  ≤7.0% 41 (44.6) 47 (35.9) 37 (45.1) 10 (20.4)
  7.1–8.0% 20 (21.7) 34 (26.0) 21 (25.6) 13 (26.5)
  >8.0% 25 (27.2) 46 (35.1) 22 (26.8) 24 (49.0)
  Missing 6 (6.5) 4 (3.0) 2 (2.4) 2 (4.1)
  Serum creatinine >2.0 mg/dL, n (%) 10 (10.9) 8 (6.1) 5 (6.1) 3 (6.1) 0.20 0.51∫
Other concurrent medications
  Sulfonylurea, n (%) 27 (29.3) 79 (60.3) 41 (50.0) 38 (77.6) <0.01 <0.01
  Insulin, n (%) 10 (10.9) 20 (15.3) 8 (9.8) 12 (24.5) 0.34 0.05
  Other OHAs, n (%) 2 (2.2) 7 (5.3) 4 (4.9) 3 (6.1) 0.31∫ 0.46∫
  Statins, n (%) 27 (29.3) 98 (74.8) 57 (69.5) 41 (83.7) <0.01 <0.01
  ACE inhibitors, n (%) 12 (13.0) 49 (37.4) 23 (28.1) 26 (53.1) <0.01 <0.01
  Angiotensin-receptor blockers, n (%) 11 (12.0) 24 (18.3) 11 (13.4) 13 (26.5) 0.20 0.06
Continued
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most plausible hypothesis of a decrease risk of severe bleeding in metformin-exposed diabetic dengue individuals 
can be collectively explained by these pleiotropic actions of metformin, which could interact and inhibit the path-
ogenic mechanisms of dengue infection that lead to severe bleeding manifestations.
Our study has several strengths. Firstly, to our knowledge, this is the first observational study to explore the 
relationship between metformin exposure and dengue severity in adults. Secondly, severe dengue was analyzed 
with two different dengue severity classifications. Thirdly, finding of a dose-response relationship provides strong, 
biologically plausible support for the link between metformin use and reduced risk of developing severe dengue49. 
Fourthly, since the standardized dengue care path was used for clinical documentation in TTSH during the whole 
study period, the clinical and laboratory data for the dengue outcome severity was consistent with minimal out-
come information bias. Lastly, evidence of significant reduction in dengue severity associated with metformin 
from this study gives insights to advance further studies.
The current study had several limitations with the first being the retrospective nature with missing data being 
unavoidable. Other limitations included the lack of data to adjust for the effect of different dengue serotypes 
on disease severity as patient-specific dengue serotype data was not available for the whole study population. 
However, the year of presentation to hospital for each patient was used as a surrogate indicator to estimate the dif-
ferent circulating dengue serotypes in each epidemic year. Similarly, potential effect of prior serostatus on disease 
severity was not described as serostatus is not routinely investigated in clinical practice. Although compliance of 
metformin was unknown, metformin usage was ascertained by using not only medication prescription database 
system but also medication reconciliation records performed on the first day of hospital admission before clinical 
outcomes developed by the trained pharmacists; as such risk of metformin misclassification is low. Additionally, 
Variables
Non-users Users Users (n = 131)
P1 P2(n = 92) (n = 131)
≤1500 mg 
(n = 82)
>1500 mg 
(n = 49)
WHO dengue severity
WHO 1997 dengue classification, n (%)
Dengue hemorrhagic fever/dengue shock syndrome 28 (30.4) 39 (29.8) 23 (28.1) 16 (32.6) 0.92 0.85
    ▪ Hemorrhagic manifestations 41 (44.6) 54 (41.2) 35 (42.7) 19 (38.8) 0.62 0.80
    ▪ Plasma leakage 48 (52.2) 65 (49.6) 38 (46.3) 27 (55.1) 0.71 0.58
WHO 2009 dengue classification, n (%)
Severe dengue 39 (42.4) 37 (28.2) 26 (31.7) 11 (22.4) 0.03 0.05
    ▪ Severe bleeding 19 (20.7) 12 (9.2) 8 (9.8) 4 (8.2) 0.02 0.05
    ▪ Severe plasma leakage 35 (38.0) 50 (38.2) 28 (34.2) 22 (44.9) 0.99 0.47
    ▪ Severe organ impairment 19 (20.7) 19 (14.5) 13 (15.8) 6 (12.2) 0.23 0.42
Epidemic year
Year of presentation, n (%)
0.07 0.15  2004, 2005, 2006, 2013 (DENV-1) 64 (69.6) 105 (80.1) 64 (78.1) 41 (83.7)
  2007, 2008, 2012 (DENV-2) 28 (30.4) 26 (19.9) 18 (22.0) 8 (16.3)
Table 1. Baseline demographic and clinical characteristics of metformin non-users and users; and users 
with standard prescribed metformin dose (≤1500 mg) and high prescribed metformin dose (>1500 mg). 
P1, statistical test between non-users and users; P2, statistical test between non-users, standard prescribed 
metformin dose (≤1500 mg) and high prescribed metformin dose (>1500 mg) users. †Mann-Whitney U test. 
‡Kruskal-Wallis test. ∫Fisher’s exact test. Other OHAs include thaizolidinediones, alpha-glucosidase inhibitors, 
dipeptidyl peptidase-4 (DPP-4) inhibitors and meglitinides.
Exposure
No of 
patients
No (%) of 
severe dengue Crude RR (95% CI) P value
Adjusted RRa 
(95% CI) P value
Adjusted RRb 
(95% CI) P value
Metformin use:
Non users 92 39 (42.4) 1.00 1.00 1.00
Users 131 37 (28.2) 0.67 (0.46–0.96) 0.03 0.64 (0.45–0.93) 0.02 0.60 (0.37–0.98) 0.04
Metformin daily doses:
Non users 92 39 (42.4) 1.00 1.00 1.00
≤1500 mg 82 26 (31.7) 0.75 (0.50–1.11) 0.15 0.71 (0.47–1.05) 0.09 0.64 (0.39–1.04) 0.07
>1500 mg 49 11 (22.5) 0.53 (0.30–0.94) 0.03 0.53 (0.30–0.94) 0.03 0.50 (0.25–0.99) 0.05
Doses (linear) 131 37 (28.2) 0.73 (0.57–0.95) 0.02 0.72 (0.56–0.94) 0.02 0.69 (0.49–0.98) 0.04
Table 2. Risk ratio for association between metformin exposure and severe dengue manifestations based on 
WHO 2009 dengue criteria. aAdjusted for age, gender, ethnicity. bAdjusted for age, gender, ethnicity, Charlson’s 
comorbidity index and diabetes complications severity index groups, nephropathy, hyperlipidemia, serum 
creatinine >2.0 mg/dL, HbA1c group, concurrent medications usage including statins, ACEI, sulfonylurea and 
insulin, and year of presentation.
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dengue severity classification was performed retrospectively with available clinical and laboratory data with a risk 
of outcome misclassification bias although it could be minimal as standardized dengue care path was used in the 
whole study period. Furthermore, as with any observational studies, there is potential residual confounding with 
respect to unknown confounding variables that were not collected for the present study. Finally, there is a risk of 
channelling bias i.e. prescription of metformin is dependent on patient’s characteristics such as age, gender, eth-
nicity, presence of comorbidities and diabetes related complications but was reduced by adjusting these potential 
confounding variables.
The study included only adult DM patients presenting with dengue to a single hospital. Dengue cases in this 
study may not be representative of dengue-infected individuals in the general population, because there may 
be mild or asymptomatic dengue patients with DM. Hence, the study results may not be generalizable to other 
populations of adult dengue patients with DM. Finally, the study was not sufficiently powered to examine the 
interactions and different effects metformin might exert on different subgroups of patients, for instance, based on 
gender, age, ethnic groups and DM complications.
Metformin is an essential drug to manage diabetic patients. This study provides preliminary evidence of a 
reduced risk of severe dengue among metformin users, and also on an inverse dose-response relationship. As 
dengue burden is rising1 and prevalence of diabetes mellitus is growing worldwide, the study findings are of major 
importance to the public health.
To date, no curative measure has been shown to be effective in treating dengue infection and supportive man-
agement is still the mainstay treatment option. Observational and interventional studies have also proved that 
prophylactic platelet transfusion is ineffective in preventing severe bleeding while adverse events are more com-
monly observed in transfused patients23,50–52. Our study suggested the potential protective effect of metformin 
on dengue severity particularly on severe bleeding. For future research, preclinical studies could be employed to 
evaluate the possible biological mechanism link between metformin use and risk of severe dengue.
In summary, our study findings showed that usage of metformin at presentation was associated with lower 
risk of developing severe dengue in hospitalized adult dengue diabetic patients, compared with non-users, in the 
absence of prior serostatus knowledge. In addition, a significant inverse dose-response relationship was noted. 
The results also suggest the difference in severe bleeding may be a factor in explaining the lower risk of severe 
dengue among metformin users.
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